AIM Stock Forecast & Price Target

AIM ImmunoTech is attractive because it is concentrating its development efforts on Ampligen for late-stage pancreatic cancer, a large unmet need that caused more than 450,000 deaths worldwide as recently as 2022. The ongoing DURIPANC Phase 2 study, run with AstraZeneca and Erasmus MC, has enrolled 18 subjects, the final patient was dosed in June 2026, and key clinical data are expected in Q1 2027 with overall survival data in Q3 2027, giving the stock identifiable catalyst points. Fundamentally, positive early trial signals, multiple additional oncology studies underway, and a balance sheet showing $6 million in cash and $4 million in debt after raising about $6 million in Q2 support a favorable risk-reward setup despite the long development path.

AIM ImmunoTech is an early-stage, clinical development company with minimal revenue, which leaves it highly dependent on future trial success and external financing rather than recurring commercial cash flow. Its Q2 2026 results, reported on August 10 for the June quarter, showed a net loss of $7 million, or $(0.43) per share, materially worse than the $(0.12) to $(0.17) estimates, underscoring weak operating leverage and ongoing dilution or liquidity pressure. The outlook is also weighed down by substantial execution risk across safety, efficacy, regulatory approval, reimbursement, and commercialization, while competition and shifting biotech sentiment further increase the likelihood of persistent financial stress.